
Pharma Pulse 7/22/24: Global Diabetes & Obesity Therapeutics Study, Is There a Correlation Between Medical Debt and Delayed Mental Health Care? & more
The latest news for pharma industry insiders.
JAMA study aims to determine whether financial barriers impact access to mental health services.
Boehringer Ingelheim’s high- and low-concentration adalimumab-adbm will be available through GoodRx for $550 for two-pack, which represents a 92% discount from the Humira list price.
Donald Trump’s vice-presidential pick has indicated he favors a hands-off approach to A.I. but also wants to increase scrutiny of the biggest tech firms in the field.
The "Growth Opportunities in Global Diabetes and Obesity Therapeutics, 2024 2028" report has been added to ResearchAndMarkets.com's offering.
This study aims to identify the primary growth opportunities that will drive the diabesity market in the near future. The study also aims to highlight the most prominent and emerging business models prevalent across the market that will enable industry stakeholders to enhance their geographic coverage in terms of patient outreach and address the challenges of limited patient access.
Ugly veggies and fruits are just as tasty 😋 and nutritious!Toss them on the grill this summer and enjoy.
Learn more ways to reduce food waste: fda.gov/food…
Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor
Newsletter
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.

